1195768-20-7

Basic information

• Product Name: N-(3-(2-(2-chloropyriMidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonaMide
• Synonyms: N-(3-(2-(2-chloropyriMidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonaMide
• CAS NO: 1195768-20-7
• Molecular Formula: C₁₈H₁₁ClF₃N₃O₃S
• Molecular Weight: 441.8114496
• Mol File: 1195768-20-7.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 609.2±65.0 °C(Predicted)
• Appearance: /
• Density: 1.567±0.06 g/cm3(Predicted)
• PKA: 6.61±0.10(Predicted)
• CAS DataBase Reference: N-(3-(2-(2-chloropyriMidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-(2-(2-chloropyriMidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonaMide(1195768-20-7)
• EPA Substance Registry System: N-(3-(2-(2-chloropyriMidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonaMide(1195768-20-7)

Safety Data

• Hazardous Substances Data: 1195768-20-7(Hazardous Substances Data)

Usage

General Description

N-(3-(2-(2-chloropyrimidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide, commonly known as a chloropyrimidinyl compound, is a chemical compound that includes a wide array of different molecular structures, such as sulfonamides, fluorochemicals, and chloropyrimidines. The highly specific nature of this compound suggests that it is likely used in specialized industries or fields of study. Its exact properties would depend on the specifics of the molecule, as even small changes in chemical structure can lead to significant differences in physical and chemical properties. However, due to its complexity, information on its exact uses and properties is not readily available in general resources. A more detailed examination into scientific literature or industry-specific resources may provide further information.

Upstream product

• 317-46-4 2-fluoro-3-nitro-benzoic acid 
• 437-86-5 2-fluoro-3-nitrotoluene 
• 946126-94-9 2-fluoro-3-nitrobenzoic acid methyl ester 
• 372-18-9 1,3-Difluorobenzene 
• 161957-56-8 3-bromo-2-fluorobenzoic acid 
• 206551-41-9 2-fluoro-3-bromobenzoic acid methyl ester 
• 1042055-86-6 methyl 3-((tert-butoxycarbonyl)amino)-2-fluorobenzoate 
• 60230-36-6 2,6-difluorobenzene-1-sulfonyl chloride 
• 914223-43-1 3-amino-2-fluoro benzoic acid 
• 13036-57-2 2-chloro-4-methylpyrimidine 
• 1195768-19-4 3-(2,6-difluorobenzenesulfonamido)-2-fluorobenzoic acid methyl ester 

Downstream Products

• 1195768-23-0 N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1 ,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide 
• 1195768-21-8 N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(tetrahydro-2H-pyran-4-yl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide 
• 1244644-50-5 C₃₁H₂₈F₃N₇O₃S₂ 
• 1195768-22-9 N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(1-methylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide 
• 1195768-06-9 N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonic acid 
• 1195765-45-7 dabrafenib 
• 1195764-77-2 2,6-Difluoro-N-{2-fluoro-3-[2-(1-methylethyl)-5-(2-{[2-(methylsulfonyl)ethyl]amino}-4-pyrimidinyl)-1,3-thiazol-4-yl]phenyl}benzenesulfonamide 
• 1423120-07-3 N-(3-(2-tert-butyl-5-(2-chloropyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide-d₉ 
• 1423119-98-5 N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide-d₉ 
• 1195769-46-0 N-{3-[2-(1,1-dimethylethyl)-5-(2-ethenyl-4-pyrimidinyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide 
• 1195767-33-9 N-[3-(2-(1,1-dimethylethyl)-5-{2-[2-(methylsulfonyl)ethyl]-4-pyrimidinyl}-1,3-thiazol-4-yl)-2-fluorophenyl]-2,6-difluorobenzenesulfonamide 
• 1195767-08-8 ethyl 3-{4-[4-(3-{[(2,6-difluorophenyl)sulfonyl]amino}-2-fluorophenyl)-2-(1,1-dimethylethyl)-1,3-thiazol-5-yl]-2-pyrimidinyl}propanoate 

Relevant articles and documents

C-TERMINAL SRC KINASE INHIBITORS

Provided herein are novel C-terminal Srk Kinase (CSK) inhibitors, e.g., having Formula G, I, II, or III. Also provided are methods of preparing the novel CSK inhibitors and method of using the novel CSK inhibitors for treating diseases or disorder such as cancer or for promoting immune response in a subject in need thereof. (G)

COMBINATION OF RIBOCICLIB AND DABRAFENIB FOR TREATING OR PREVENTING CANCER

The present disclosure relates to pharmaceutical combinations comprising a cyclin dependent kinase 4/6 (CDK4/6) inhibitor compound, (b) a B-Raf inhibitor compound, and optionally (c) an alpha-isoform specific phosphatidylinositol 3 -kinase (PI3K) inhibitor compound, for the treatment or prevention of cancer, as well as related pharmaceutical compositions, uses, and methods of treatment or prevention of cancer.

COMBINATIONS OF TRAMETINIB, PANITUMUMAB AND DABRAFENIB FOR THE TREATMENT OF CANCER

A novel combination comprising a B-Raf inhibitor, particularly N-{3-[5-(2- Amino-4-pyrimidinyl)-2-(1, 1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6- difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and/or the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;- 2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and panitumumab (Vectibix); pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf and/or EGFR is beneficial, eg. cancer.